BG102880A - Cation virosomes as transfer systems for genetic materials - Google Patents
Cation virosomes as transfer systems for genetic materialsInfo
- Publication number
- BG102880A BG102880A BG102880A BG10288098A BG102880A BG 102880 A BG102880 A BG 102880A BG 102880 A BG102880 A BG 102880A BG 10288098 A BG10288098 A BG 10288098A BG 102880 A BG102880 A BG 102880A
- Authority
- BG
- Bulgaria
- Prior art keywords
- virosomes
- cation
- preparation
- transfer systems
- genetic materials
- Prior art date
Links
- 239000000277 virosome Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 150000001768 cations Chemical class 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96107282 | 1996-05-08 | ||
| PCT/EP1997/002268 WO1997041834A1 (en) | 1996-05-08 | 1997-05-04 | Cationic virosomes as transfer system for genetic material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG102880A true BG102880A (en) | 1999-05-31 |
Family
ID=8222763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102880A BG102880A (en) | 1996-05-08 | 1998-10-29 | Cation virosomes as transfer systems for genetic materials |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6210708B1 (https=) |
| EP (1) | EP0902682A2 (https=) |
| JP (1) | JP2000509404A (https=) |
| KR (1) | KR100536983B1 (https=) |
| CN (1) | CN1271992C (https=) |
| AR (1) | AR007054A1 (https=) |
| AU (1) | AU710170B2 (https=) |
| BG (1) | BG102880A (https=) |
| BR (1) | BR9709224A (https=) |
| CA (1) | CA2253561A1 (https=) |
| CO (1) | CO4600638A1 (https=) |
| CZ (1) | CZ299809B6 (https=) |
| EA (1) | EA003130B1 (https=) |
| GT (1) | GT199700058A (https=) |
| HR (1) | HRP970234B1 (https=) |
| HU (1) | HUP9901790A3 (https=) |
| ID (1) | ID17934A (https=) |
| NO (1) | NO327726B1 (https=) |
| NZ (1) | NZ332666A (https=) |
| OA (1) | OA10916A (https=) |
| PA (1) | PA8429201A1 (https=) |
| PE (1) | PE65198A1 (https=) |
| PL (1) | PL199201B1 (https=) |
| SK (1) | SK152698A3 (https=) |
| SV (1) | SV1997000032A (https=) |
| TN (1) | TNSN97080A1 (https=) |
| WO (1) | WO1997041834A1 (https=) |
| ZA (1) | ZA973885B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113347A1 (en) * | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| AU9224398A (en) * | 1997-09-08 | 1999-03-29 | Promega Corporation | Method of (in vivo) transformation utilizing lipid vehicles |
| SE513149C2 (sv) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
| GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| HUP0202809A2 (hu) * | 1999-10-08 | 2002-12-28 | Nika Health Products Limited | Kationos DOSPER-viroszómák |
| ES2202218T3 (es) * | 1999-12-17 | 2004-04-01 | Schott Glas | Capsula fulminante activable inductivamente para sistemas de retencion de pasajeros y circuito de prueba para esta capsula fulminante. |
| EP1252897A4 (en) * | 2000-01-21 | 2003-07-30 | Hisamitsu Pharmaceutical Co | MEDICINES FOR GENE THERAPY |
| EP1409653A4 (en) * | 2001-07-23 | 2006-05-03 | Onyx Pharma Inc | IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS |
| KR100411234B1 (ko) * | 2001-08-14 | 2003-12-18 | 한국과학기술원 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
| WO2003038103A1 (en) * | 2001-10-29 | 2003-05-08 | Atso Raasmaja | Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers |
| US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| PL377161A1 (pl) * | 2002-11-21 | 2006-01-23 | Pevion Biotech Ltd. | Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| EP1687017B1 (en) | 2003-10-24 | 2013-03-06 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| US20070172520A1 (en) * | 2005-11-18 | 2007-07-26 | University Of South Florida | Immunotargeting of Nonionic Surfactant Vesicles |
| CA2663034C (en) | 2006-09-15 | 2016-05-03 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| KR101242113B1 (ko) * | 2010-10-22 | 2013-03-19 | 고마바이오텍(주) | 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체 |
| WO2013032643A2 (en) * | 2011-08-31 | 2013-03-07 | Dicerna Pharmaceuticals, Inc. | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| WO2013050048A2 (en) * | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| WO2018060213A1 (en) | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
| CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| DK0538437T3 (da) * | 1991-05-08 | 2000-02-07 | Schweiz Serum & Impfinst | Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem |
| WO1993014744A1 (en) | 1992-02-04 | 1993-08-05 | Chiron Corporation | Non-toxic lipid vaccine formulations |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1995002698A1 (en) * | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| ATE223701T1 (de) * | 1994-05-31 | 2002-09-15 | Inex Pharmaceutical Corp | Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen |
| FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
-
1997
- 1997-05-04 JP JP9539526A patent/JP2000509404A/ja active Pending
- 1997-05-04 CA CA002253561A patent/CA2253561A1/en not_active Abandoned
- 1997-05-04 SK SK1526-98A patent/SK152698A3/sk unknown
- 1997-05-04 HU HU9901790A patent/HUP9901790A3/hu unknown
- 1997-05-04 KR KR1019980708906A patent/KR100536983B1/ko not_active Expired - Fee Related
- 1997-05-04 CZ CZ0361498A patent/CZ299809B6/cs not_active IP Right Cessation
- 1997-05-04 NZ NZ332666A patent/NZ332666A/xx unknown
- 1997-05-04 CN CNB971962324A patent/CN1271992C/zh not_active Expired - Fee Related
- 1997-05-04 EP EP97921852A patent/EP0902682A2/en not_active Withdrawn
- 1997-05-04 BR BR9709224A patent/BR9709224A/pt unknown
- 1997-05-04 WO PCT/EP1997/002268 patent/WO1997041834A1/en not_active Ceased
- 1997-05-04 PL PL329853A patent/PL199201B1/pl not_active IP Right Cessation
- 1997-05-04 EA EA199800992A patent/EA003130B1/ru not_active IP Right Cessation
- 1997-05-04 AU AU27766/97A patent/AU710170B2/en not_active Ceased
- 1997-05-06 ZA ZA973885A patent/ZA973885B/xx unknown
- 1997-05-07 HR HR970234A patent/HRP970234B1/xx not_active IP Right Cessation
- 1997-05-07 SV SV1997000032A patent/SV1997000032A/es unknown
- 1997-05-07 TN TNTNSN97080A patent/TNSN97080A1/fr unknown
- 1997-05-07 GT GT199700058A patent/GT199700058A/es unknown
- 1997-05-07 CO CO97024481A patent/CO4600638A1/es unknown
- 1997-05-07 PE PE1997000354A patent/PE65198A1/es not_active Application Discontinuation
- 1997-05-08 AR ARP970101917A patent/AR007054A1/es not_active Application Discontinuation
- 1997-05-08 PA PA19978429201A patent/PA8429201A1/es unknown
- 1997-05-09 ID IDP971533A patent/ID17934A/id unknown
-
1998
- 1998-10-29 BG BG102880A patent/BG102880A/xx unknown
- 1998-11-04 NO NO19985137A patent/NO327726B1/no not_active IP Right Cessation
- 1998-11-06 OA OA9800214A patent/OA10916A/en unknown
-
1999
- 1999-10-08 US US09/414,872 patent/US6210708B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG102880A (en) | Cation virosomes as transfer systems for genetic materials | |
| Seyedin et al. | Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. | |
| Butler | The nature and significance of osteopontin | |
| Kasugai et al. | Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter | |
| Ihle et al. | Phenotypic characteristics of cell lines requiring interleukin 3 for growth. | |
| Nagata et al. | Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture | |
| Brunner et al. | Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells | |
| Wang et al. | Purification and characterization of other distinct bone-inducing factors. | |
| Nilsen-Hamilton et al. | Selective stimulation by mitogens of incorporation of 35S-methionine into a family of proteins released into the medium by 3T3 cells | |
| CA2457632C (en) | Identification and isolation of somatic stem cells and uses thereof | |
| Guy et al. | Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth. | |
| Stadie et al. | Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP‐GalNAc: polypeptide N‐acetylgalactosaminyltransferase from milk or mammary carcinoma cells | |
| ZA953629B (en) | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies | |
| WO2002078598A3 (en) | Peptides and antibodies to muc 1 proteins | |
| AU2002355970A1 (en) | Identification and isolation of somatic stem cells and uses thereof | |
| AU3509995A (en) | Overexpression of mammalian and viral proteins | |
| KR20010030617A (ko) | 유방 특이적으로 분비되는 유방암 단백질인 마마글로빈 | |
| Atherton et al. | Dipeptidyl peptidase IV expression identifies a functional sub‐population of breast fibroblasts | |
| Schwartz-Albiez et al. | Differential expression of annexins I and II in normal and malignant human mammary epithelial cells | |
| WO2000043499A3 (en) | ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD | |
| GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
| Okamura et al. | Localization of a maturation-dependent epididymal sperm surface antigen recognized by a monoclonal antibody raised against a 135-kilodalton protein in porcine epididymal fluid | |
| Clark et al. | Characterization of murine pregnancy decidua transforming growth factor b. I. Transforming growth factor b2-like molecules of unusual molecular size released in bioactive form | |
| DE3751319D1 (de) | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. | |
| Bocchini et al. | Glial fibrillary acidic protein and its encoding mRNA exhibit mosaic expression in a glioblastoma multiform cell line of clonal origin |